The prognostic significance of determining DNA content in breast cancer by DNA image cytometry: The role of high grade aneuploidy in node negative breast cancer

Journal of Clinical Pathology

Volumn 60, Issue 6, 2007, Pages 649-655

  Yildirim Assaf, Selma ^a   Coumbos, Alexandra ^a   Hopfenmüller, Werner ^a   Foss, Hans Dieter ^a   Stein, Harald ^a   Kühn, Wolfgang ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANEUPLOIDY; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMETRY; DNA CONTENT; DNA DETERMINATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMAGE CYTOMETRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 34250885138     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.035550     Document Type: Article

References (54)

1. Feuer EJ, Wun LM, Boring CC, et al. The lifetime risk of developing breast cancer. J Natl Cancer Inst 1993;85:892-7.
2. Yuan J, Hennessy C, Givan AL, et al. Predicting outcome for patients with node negative breast cancer: a comparative study of the value of flow cytometry and cell image analysis for determination of DNA ploidy. Br J Cancer 1992;65:461-5.
3. Moore MP, Kinne DW. Axillary lymphadenectomy: a diagnostic and therapeutic procedure. J Surg Oncol 1997;66:2-6.
4. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary node-negative breast cancer. N Engl J Med 1992;326:1756-61.
5. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993;85:1206-19.
6. Aubele M, Auer G, Falkmer U, et al. Identification of a low-risk group of stage I breast cancer patients by cytometrically assessed DNA and nuclear texture parameters. J Pathol 1995;177:377-84.
7. Aubele M, Auer G, Voss A, et al. Different risk groups in node negative breast cancer: prognostic value of cytophotometrically assessed DNA, morphometry and texture. Int J Cancer 1995;63:7-12.
8. Ottesen GL, Christensen IJ, Larsen JK, et al. DNA aneuploidy in early breast cancer. Br J Cancer 1995;72:832-9.
9. Burger G, Aubele M, Jutting U, et al. Interactive cytometry, chance or evil of bias? Pathol Res Pract 1992;188:391- 5.
10. Auer GU, Caspersson TO, Wallgren AS. DNA content and survival in mammary carcinoma. Anal Quant Cytol 1980;2:161-5.
11. Fallenius AG, Auer GU, Carstensen JM. Prognostic significance of DNA measurements in consecutive breast cancer patients. Cancer 1988;62:331-41.
12. von Rosen A, Rutqvist LE, Carstensen J, et al. Prognostic value of nuclear DNA content in breast cancer in relation to tumour size, nodal status, and estrogen receptor content. Breast Cancer Res Treat 1989;13:23-32.
13. Blegen H, Will JS, Ghadimi BM, et al. DNA amplifications and aneuploidy, high proliferative activity and impaired cell cycle control characterize breast carcinomas with poor prognosis. Anal Cell Pathol 2003;25:103-14.
14. Singletary ES, Allred C, Ashley P, et al. Revision of the American Joint Committee on cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-36.
15. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11:359-77.
16. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987;8:138-40.
17. Pichon MF, Broet P, Magdelenat H, et al. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 1996;73:1545-51.
18. Gerdes J, Lelle RJ, Pickartz H, et al. Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. J Clin Pathol, 39:977-80.
19. Feulgen R, Rossenbeck H. Mikroskopisch-chemischer Nachweis einer Nukleinsäure vom Typus der Thymonukleinsäure und die darauf beruhende elektive Färbung von Zellkernen in mikroskopischen Präparaten. Z Physiol Chem 1924;135:203-48.
20. Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol 1941;42:193-206.
21. Giroud F, Haroske G, Reith A, et al. Part I: Basic considerations and recommendations for preparation, measurement and interpretation. Anal Cell Pathol 1998;17:189-200.
22. Giroud F, Haroske G, Reith A, et al. Part II: Specific recommendations for quality assurance. Anal Cell Pathol 1998;17:201-8.
23. Haroske G, Baak JPA, Danielsen H, et al. Fourth updated ESACP consensus report on diagnostic DNA image cytometry. Anal Cell Pathol 2001;23:89-95.
24. Nie HH, Hadlai H, Jenkins JG, et al. SPSS (Statistical Package for the Social Sciences). New York, NY: McGraw-Hill, 1979.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
26. Brennan P, Silman A. Statistical methods for assessing observer variability in clinical measures. BMJ 1992;304:1491-4.
27. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
28. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
29. Baak JP, Van Dop H, Kurver PH, et al. The value of morphometry to classic prognosticators in breast cancer. Cancer 1985;56:374-82.
30. Aubele M, Auer G, Hofler H. Analysis of DNA and morphometry in breast carcinoma. Histochem Cell Biol 1996;106:241-5.
31. Sigurdsson H, Baldetorp B, Borg A, et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990;322:1045-53.
32. Baak JPA, van Diest PJ, Voorhorst FJ, et al. Prospective multicenter validation of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 2005;23:5993-6001.
33. Stanton PD, Cooke TG, Oakes SJ, et al. Lacl of prognostic significance of DNA ploidy and S-phase fraction in breast cancer. Br J Cancer 1992;66:925-9.
34. Goldhirsch A, Glick JH, Gelber RD, and Panel Members, et al. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Ann Oncol 2005;16:1569-83.
35. Bofin AM, Ytterhus B, Martin C, et al. Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol 2004;122:110-19.
36. Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004;240:306-12.
37. Hedley DW, Clark GM, Cornelisse CJ, et al. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry 1993;14:482-5.
38. Shankey TV, Rabinovitch PS, Bagwell B, et al. Guidelines for implementation of clinical DNA cytometry. Cytometry 1993;14:472-7.
39. Auer G, Einhorn N, Nilsson B, et al. Biological malignancy grading in early-stage ovarian carcinoma. Acta Oncol 1996;35:93-8.
40. Mandard AM, Denoux Y, Herlin P, et al. Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial: multivariate analysis with Ki-67 index, mitotic count, and microvessel density. Cancer 2000;89:1748-57.
41. Pinto AE, Andre S, Soares J. Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients. J Clin Pathol 1999;52:604-11.
42. Beerman H, Kluin PM, Hermans J, et al. Prognostic significance of DNA-ploidy in a series of 690 primary breast cancer patients. Int J Cancer 1990;45:34-9.
43. Lorenzato M, Abboud P, Masure M, et al. Image cytometry detection of breast cancer cells with >5c DNA content and minor DNA stemlines. Anal Quant Cytol Histol 2000;22:199-205.
44. Casperson TO. History of the development of cytophotometry from 1935 to the present. Anal Quant Cytol Histol 1987;9:2-6.
45. Baldetorp B, Ferno M, Fallenius A, et al. Image cytometric DNA analysis in human breast cancer analysis may add prognostic information in diploid cases with low S-phase fraction by flow cytometry. Cytometry 1992;13:577-85.
46. Sen S. Aneuploidy and cancer. Curr Opin Oncol 2000;12:82-8.
47. Keyhani-Rofagha S, O'Toole RV, Farrar WB, et al. Is DNA ploidy an independent prognostic indicator in infiltrative node-negative breast adenocarcinoma? Cancer 1990;65:1577-82.
48. Magennis DP. Nuclear DNA in histological and cytological specimen: measurement and prognostic significance. Br J Biomed Sci 1997;54:140-8.
49. Millot C, Dufer J. Clinical applications of image cytometry to human tumour analysis. Histol Histopathol 2000;15:1185-200.
50. Baldetorp B, Ferno M, Bendahl PO, et al. Proliferative index obtained by DNA image cytometry. Does it add prognostic information in Auer IV breast cancer? Am J Epidemiol 1998;20:144-52.
51. Seker H, Odetayo MO, Petrovic D, et al. Assessment of nodal involvement and survival analysis in breast cancer patients using image cytometric data: statistical, neural network and fuzzy approaches. Anticancer Res 2002;22:433-8.
52. Steinbeck RG, Auer GU, Zetterberg AD. Reliability and significance of DNA measurements in interphase nuclei and division figures in histological sections. Eur J Cancer 1999;35:787-95.
53. Kronenwett U, Huwendiek S, Ostring C, et al. Improved grading of breast adenocarcinomas based on genomic instability. Cancer Res 2004;64:904-9.
54. Kronenwett U, Huwendiek S, Castro J, et al. Characterisation of breast fine needle aspiration biopsies by centrosome aberrations and genomic instability. Br J Cancer 2005;92:389-9.